Microbot Medical Inc. · NASDAQ:MBOT
Microbot Medical — Investor Presentation (April 2022)
11 slides from Microbot Medical's investor presentation, Apr 12, 2022
Slide 1: Microbot Medical: Access-Ability for All
microbot medical ACCESS-ABILITY FOR ALL’ HAREL GADOT Chairman of the Board of Directors
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, relating to future events or the future financial performance and operations of Micr
Slide 3: Surgical Robotics Today
SURGICAL ROBOTICS TODAY + Large, cumbersome footprint + Dedicated room, dedicated staff + Time consuming to set up and use + Long and expensive learning curve
Slide 4: Endo-Vascular: Total Addressable Market (US)
ENDO-VASCULAR: TOTAL ADDRESSABLE MARKET (US) > Coronary > Peripheral > Neuro + Medtech 360 Reports
Slide 5: Multiple Barriers Leading to Low Penetration
MULTIPLE BARRIERS LEADING TO LOW PENETRATION Special training, > long learning curve Cumbersome and expensive disposables > 5 M = Extended set-up time > Dedicated > infrastructure > Coronary > Peripheral Large footprint > Neiiro Capital expense >
Slide 6: Multiple Barriers Leading to Low Penetration
MULTIPLE BARRIERS LEADING TO LOW PENETRATION User friendly > No additional > disposables Sterile Kit > No dedicated > infrastructure Small footprint [> Fully disposable > ‘The LIBERTY system isnot cleared for marketing or any cnial use
Slide 7: Eliminating Barriers, Allowing Access
ELIMINATING BARRIERS, ALLOWING ACCESS
Slide 8: Accessibility: The Future of Surgical Robotics
ACCESSIBILITY: THE FUTUR SURGICAL ROBOTICS
Slide 9: Access-Ability for All
ACCESS-ABILITY FOR ALL™
Slide 10: Physician feedback on the LIBERTY system
“lm very, very pleased with the first experience; it's an easy setup of the system.” “For [the] young generation, it would probably be easier to do with the robot than to do it manually.” Dr. Dmitry J. Rabkin Vascular & Interventional Radiology ‘The LIBERTY system isnot cleared for marketing or any
Slide 11: Road to Commercialization
ROAD TO COMMERCIALIZATION Pre-Submission Finalize U.S. Food and Drug Administration (FDA) pre- submission for the LIBERTY® Robotic System IP Portfolio Expand and protect the Company's global IP portfolio in global jurisdictions, which creates significant barriers to entry Trials Initiate pre-clinica
Microbot Medical — Investor Presentation (April 2022) on 6ix